Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

E-MTAB-7386

ABSTRACT: RNAseq of tumor samples from CT26 syngeneic mouse treated with a PI3Ka/d inhibitor (AZD8835)

PROVIDER: E-MTAB-7386 | ExpressionAtlas | 2019-01-16

REPOSITORIES: ExpressionAtlas

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	E-MTAB-7386-analysis-methods.tsv	Tabular
	E-MTAB-7386-analytics.tsv	Tabular
	E-MTAB-7386-atlasExperimentSummary.Rdata	Rdata
	E-MTAB-7386-configuration.xml	Xml
	E-MTAB-7386-g3_g1-mvaPlot.png	Other

Items per page:

1 - 5 of 34

Similar Datasets

RNAseq of tumor samples from CT26 syngeneic mouse treated with a PI3Ka/d inhibitor (AZD8835)

Project description:RNAseq of tumor samples from CT26 syngeneic mouse treated with a PI3Ka/d inhibitor (AZD8835)

| PRJEB29676 | ENA

Effects of AKT/WEE1 inhibitors or ALDH inhibitor combined with PD-1 antibody on melanoma

Project description:The effects of AKT/WEE1 inhibitors or ALDH inhibitor combined with PD-1 antibody on melanoma were examined. Mouse B16F10 melanoma cells were subcutaneously injected into C57/B6 mice. When tumors were well-vascularized, mice were treated with anti-PD-1, AKT I (AZD5363)+WEE1 I (MK1775), AZD5363+MK1775+anti-PD-1, ALDH I (KS100), KS100+ anti-PD-1 daily. Mice were sacrificed when tumors in the control group (DMSO treated) reached 2000 mm3 and tumors were removed. RNA was extracted from tumor samples and gene expression was analized using RNAseq analysis.

2023-12-31 | GSE199096 | GEO

Homo sapiens

Project description:Whole Exome Sequencing on BRAF+MEK inhibitor treated tumor samples

| PRJNA267020 | ENA

Expression data from tumor samples treated with a tankyrase inhibitor in a mouse xenograft model

Project description:Expression data from tumor samples treated with a tankyrase inhibitor in a mouse xenograft model

| PRJNA454695 | ENA

Phase 1 Study of Ulixertinib (BVD 523) in Patients with Advanced Solid Malignancies

Project description:RNAseq from tumor samples of patients treated on clinical trial

2023-02-15 | GSE213797 | GEO

Phase 1 Study Combining Alisertib with Nab-Paclitaxel in Patients with Advanced Solid Malignancies (NCT01677559)

Project description:WES and RNAseq from tumor samples of patients treated on clinical trial

2021-08-20 | GSE174765 | GEO

Analysis of transcriptional changes in cell lines (in vitro) and tumors (in vivo) after treatment with interferon α gene therapy.

Project description:Three bladder cancer cell lines were treated with recombinant IFNα, LV-Ctrl or LV-IFNα and compared with control (Ctrl) samples by RNAseq. Also, vehicle treated, LV-Ctrl and LV-IFNα treated murine MB49 bladder cancer tumor model was compared by RNAseq

2022-06-05 | GSE205493 | GEO

Translation efficiency in the pancreatic tumor in response to ketogenic diet and targeting eIF4E phosphorylation

Project description:To investigate the translatome in the pancreatic tumor inresponse to ketogenidc diet and the combination of ketogenic diet with an inhibitor targeting eIF4E phosphorylation. We generated pancreatic tumor xenograftmice model, treated mice with regular chow, ketogenic diet or ketogenic diet with eFT508, an inhibitor targeting eIF4E phosphorylation. Then we performed Poly-RNAseq on the tumor isolated from mice upon different treatments.

2024-08-14 | GSE267398 | GEO

Transcriptome profiling of a mouse model of alveolar soft part sarcoma

Project description:In order to dtermine how well a mouse genetic model of alveolar soft part sarcoma (ASPS) mimics the human disease, five human ASPS tumor samples and three normal skeletal muscle samples were profiled by RNAseq and compared to samples from five mouse tumors induced by expression of ASPSCR1-TFE3 and three normal mouse skeletal muscle samples, also profiled by RNAseq.

2014-11-26 | GSE54729 | GEO

Global altered gene expression in triple-negative breast cancer tumor samples treated with CDK2 and EZH2 inhibitors

Project description:Triple-negative breast cancer cell line SUM-149 xenograft mouse model was treated with CDK2 inhibitor (dinaciclib) and EZH2 inhibitor (EPZ6438) for 10 days to examine global transcriptome alternations by RNAseq. Expression levels of more than 801 and 741 gene were altered by CDK2 inhibitor and EZH2 inhibitor treatment, respectively.Among differential changed genes induced by CDK2 inhibitor and EZH2 inhibitor, we defined top 109 common up- and down-regulated gene sets in the inhibitor-treated tumors.

2019-06-05 | GSE132194 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data